226 related articles for article (PubMed ID: 12954117)
1. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE
Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117
[TBL] [Abstract][Full Text] [Related]
2. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS.
Boado RJ; Tsukamoto H; Pardridge WM
J Pharm Sci; 1998 Nov; 87(11):1308-15. PubMed ID: 9811482
[TBL] [Abstract][Full Text] [Related]
3. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
5. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
[TBL] [Abstract][Full Text] [Related]
6. Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides.
Kim SH; Kim EJ; Hou JH; Kim JM; Choi HG; Shim CK; Oh YK
Biomaterials; 2009 Feb; 30(5):959-67. PubMed ID: 19027156
[TBL] [Abstract][Full Text] [Related]
7. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.
Juliano RL; Alahari S; Yoo H; Kole R; Cho M
Pharm Res; 1999 Apr; 16(4):494-502. PubMed ID: 10227702
[TBL] [Abstract][Full Text] [Related]
8. Hybridisation of [76Br]-labelled antisense oligonucleotides to Chromogranin A mRNA verified by RT-PCR.
Wu F; Lendvai G; Yngve U; Eriksson B; Långström B; Bergström M
Nucl Med Biol; 2004 Nov; 31(8):1073-8. PubMed ID: 15607489
[TBL] [Abstract][Full Text] [Related]
9. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
Aukunuru JV; Ayalasomayajula SP; Kompella UB
J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
[TBL] [Abstract][Full Text] [Related]
11. Synthetic oligonucleotides as therapeutics: the coming of age.
Ma DD; Rede T; Naqvi NA; Cook PD
Biotechnol Annu Rev; 2000; 5():155-96. PubMed ID: 10875000
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
13. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
14. Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?
Lavigne C; Yelle J; Sauve G; Thierry AR
AAPS PharmSci; 2002; 4(2):E9. PubMed ID: 12102618
[TBL] [Abstract][Full Text] [Related]
15. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems.
Islam A; Handley SL; Thompson KS; Akhtar S
J Drug Target; 2000; 7(5):373-82. PubMed ID: 10721799
[TBL] [Abstract][Full Text] [Related]
16. Oligonucleotide structure influences the interactions between cationic polymers and oligonucleotides.
Sundaram S; Viriyayuthakorn S; Roth CM
Biomacromolecules; 2005; 6(6):2961-8. PubMed ID: 16283715
[TBL] [Abstract][Full Text] [Related]
17. Antisense therapy in malignant diseases: status quo and quo vadis?
Tamm I
Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
[TBL] [Abstract][Full Text] [Related]
18. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
[TBL] [Abstract][Full Text] [Related]
19. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain.
Khan A; Sommer W; Fuxe K; Akhtar S
J Drug Target; 2000; 8(5):319-34. PubMed ID: 11328659
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy using antisense oligodeoxynucleotides labeled with Auger-emitting radionuclides.
Kairemo KJ; Tenhunen M; Jekunen AP
Cancer Gene Ther; 1998; 5(6):408-12. PubMed ID: 9917096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
